### MORGAN STANLEY RESEARCH ASIA/PACIFIC

Morgan Stanley India Company Private Limited+ Vipin Khare Vipin.Khare@morganstanley.com +91 22 2209 7765

Gaurav Rateria

Gaurav.Rateria@morganstanley.com +91 22 2209 7160

January 14, 2009

Stock Rating Equal-weight Industry View Cautious

# Infosys Technologies

Currency drags revenues but helps margins; Maintain EW

### What's Changed

 Price Target
 Rs1,285.00 to Rs1,351.00

 FY09e-FY11e Rupee EPS
 Up by 0.5%-1.6%

**Investment conclusion:** Infosys' 4Q revenue guidance implies a QoQ volume decline. We believe increasing training time for employees from 16 weeks to 24 is also an indication of management expectations of lower volume growth in the near-medium term. Given the macro uncertainty, we would not chase the stock at current levels. In the current environment, we believe ~Rs1,050–1,100 would be a reasonable entry price for investors with a long-term view. Maintain EW.

What's new: Management indicated that overall spending at clients could be down 4-5% in 2009 and pricing could get tougher if the macro environment worsens. Overall hiring guidance was raised to 27,000 employees for FY09e, with 20,000 campus offers (implying net adds of 5,000-7,000) in FY10e. (See result details on page 4-5). US\$ revenue run-rate for F4Q09 is now back to F4Q08 levels with 2009 budgets likely to be lower than 2008.

Where we differ: We believe revenue growth for Infosys in FY10e is likely to trend down to single digits. However, a key surprise for Infosys in F2H10 could be lower-than-expected pricing pressure post the Satyam issue as clients now may not be able to lower rates significantly by playing large vendors against their smaller peers, in our view.

What's next: MS economists now expect US GDP to contract by -2.4% in 2009. Travel and budget delays could further prolong decision cycles over the coming quarters. We would wait for the macro environment to stabilize before accumulating the stock.

### **Key Ratios and Statistics**

### Reuters: INFY.BO Bloomberg: INFO IN

India Software	
Price target	Rs1,351.00
Upside to price target (%)	10
Shr price, close (Jan 13, 2009)	Rs1,230.20
52-Week Range	Rs2,017.00-1,040.00
Sh out, dil, curr (mn)	572
Mkt cap, curr (mn)	Rs703,453
EV, curr (mn)	Rs633,233
Avg daily trading volume (mn)	Rs527

Fiscal Year ending	03/08	03/09e	03/10e	03/11e
ModelWare EPS (Rs)	81.27	102.86	107.02	111.62
Prior ModelWare EPS (Rs)	-	101.16	106.48	110.27
Consensus EPS (Rs)§	80.27	102.94	109.24	112.09
Revenue, net (Rs mn)	166,920	218,107	235,505	263,914
EBITDA (Rs mn)	52,380	70,564	72,917	80,405
ModelWare net inc (Rs mn)	46,590	58,971	61,427	64,070
P/E	17.6	12.0	11.5	11.0
P/BV	5.9	3.7	3.0	2.5
RNOA (%)	75.4	82.4	72.3	72.0
ROE (%)	41.4	42.7	32.3	27.1
EV/EBITDA	14.3	8.4	7.5	6.4
Div yld (%)	0.3	3.5	2.2	2.7
FCF yld ratio (%)	4.7	7.3	8.5	8.0
Leverage (EOP) (%)	(50.4)	(58.5) Morgan S	(65.2)	(67.5)

Unless otherwise noted, all metrics are based on Morgan Stanley ModelWare

framework (please see explanation later in this note). § = Consensus data is provided by FactSet Estimates.

e = Morgan Stanley Research estimates

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision. Customers of Morgan Stanley in the US can receive independent, third-party research on companies covered in Morgan Stanley Research, at no cost to them, where such research is available. Customers can access this independent research at www.morganstanley.com/equityresearch or can call 1-800-624-2063 to request a copy of this research.

# For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.

+= Analysts employed by non-U.S. affiliates are not registered with FINRA, may not be associated persons of the member and may not be subject to NASD/NYSE restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

January 14, 2009 Infosys Technologies

### **Financial Summary: Infosys Technologies**

### Consolidated P&L Statement (Rs m)

Year to 31 March	FY07	FY08	FY09E	FY10E	FY11E
REVENUES	138,930	166,920	218,107	235,505	263,914
% chg YoY	45.9	20.1	30.7	8.0	12.1
Cost of Services	74,580	92,070	119,429	130,088	145,486
GROSS PROFIT	64,350	74,850	98,678	105,417	118,428
Gross Margin (%)	46.3	44.8	45.2	44.8	44.9
S, G & A	20,440	22,470	28,114	32,500	38,023
% of sales	14.7	13.5	12.9	13.8	14.4
EBITDA	43,910	52,380	70,564	72,917	80,405
EBITDA margin (%)	31.6	31.4	32.4	31.0	30.5
Depreciation	5,140	5,980	7,274	8,182	9,037
EBIT	38,770	46,400	63,290	64,734	71,368
EBIT margin (%)	27.9	27.8	29.0	27.5	27.0
Other income	3,700	7,040	3,554	6,612	7,828
PBT	42,470	53,440	66,844	71,346	79,196
Тах	5,100	6,850	7,874	9,920	15,126
Eff. Tax Rate (%)	12.0	12.8	11.8	13.9	19.1
NET PROFIT	37,260	46,590	58,971	61,427	64,070
% chg YoY	51.5	25.0	26.6	4.2	4.3
Net Margin (%)	26.8	27.9	27.0	26.1	24.3
Basic EPS (Rs)	69.2	81.5	103.0	107.0	111.6
FD EPS (Rs)	67.7	81.3	102.9	107.0	111.6
EPADS (US\$)	1.52	2.04	2.22	2.25	2.43
Growth (US\$) (%)	49.5	33.7	9.0	1.5	4.3
Growth (Rs EPS) (%)	54.7	20.0	26.6	4.0	4.3

### Consolidated Cash Flow (Rs m)

Year to Mar 31	FY07	FY08	FY09E	FY10E	FY11E
PAT	37,260	46,590	58,971	61,427	64,070
Depreciation	5,140	5,980	7,274	8,182	9,037
Changes in working Capital	(10,170)	(2,530)	(2,287)	(753)	(8,658)
OP CASH FLOW	32,230	50,040	63,957	68,856	64,449
Capital Expenditure	(15,030)	(11,560)	(12,359)	(8,895)	(8,197)
Investments	(20)	720	(1,260)	-	-
INV CASH FLOW	(20,610)	(10,840)	(13,619)	(8,885)	(8,187)
Free Cash Flow	17,120	39,200	50,338	59,970	56,262
Issue of shares	1,480	-	-	-	-
Reserve Adjustments	14,120	(13,610)	17,814	970	883
Dividends paid	(15,520)	(7,580)	(24,354)	(16,492)	(19,661)
FX/Others	(60)	(7,470)	(2,000)	(1,610)	(1,610)
FIN CASH FLOW	20	(28,660)	(8,540)	(17,132)	(20,389)
NET CASH FLOW	17,140	10,540	41,798	42,838	35,873
Cash & Eq at Yr Beg	41,820	58,960	69,500	111,298	154,136
Cash & Eq at Yr End	58,960	69,500	111,298	154,136	190,009

### Consolidated Balance Sheet (Rs m)

Year to Mar 31	FY07	FY08	FY09E	FY10E	FY11E
APPLICATION OF FUNI				-	
Gross Fixed Assets	46,420	54,390	70,989	79,384	85,081
Less: Dep and Amort	18,360	19,860	25,134	31,716	39,153
Net Fixed Assets	28,060	34,530	45,855	47,668	45,928
Add: Capital WIP	9650	13240	9000	9500	12000
Total Fixed Assets	37,710	47,770	54,855	57,168	57,928
DEF TAX ASSETS	920	1,190	1,380	1,380	1,380
CURRENT ASSETS	95,460	130,900	174,735	219,864	267,169
Sundry Debtors	24,360	32,970	34,674	35,926	42,174
Cash & Bank Bal	58,960	70,220	111,298	154,136	190,009
Loans and Advances	12,140	27,710	28,763	29,802	34,985
TOTAL ASSETS	134,090	179,860	232,951	280,393	328,457
SOURCES OF FUNDS					
Current liab & prov	21,500	41,910	42,570	44,107	46,880
Current Liabilities	14,690	19,120	22,436	23,246	25,889
Provisions	6,810	22,790	20,134	20,861	20,991
Share Capital	2,860	2,860	2,860	2,860	2,860
Reserves and Surplus	109,690	135,090	187,521	233,425	278,717
SH FUNDS	112,550	137,950	190,381	236,285	281,577
TOTAL LIABILITIES	134,090	179,860	232,951	280,393	328,457


### **Key Ratios & Assumptions**

Yr to Mar31	FY07	FY08	FY09E	FY10E	FY11E
RoAE (%)	40.7	37.2	35.9	28.8	24.7
P/E	18.2	15.1	12.0	11.5	11.0
Volume (% YoY)	38.6	26.0	17.2	9.0	15.2
Avg Price Reazn(%YoY)	4.5	6.2	-2.4	-3.4	0.3
Avg FX Rate (Rs/US\$)	45.5	40.0	46.4	47.5	45.9
change (%yoy)	2.8	-12.0	15.9	2.4	-3.4
Emp Costs as % of Rev	47.4	49.8	49.6	51.3	52.5
SG&A as % of Revenue	14.7	13.5	12.9	13.8	14.4
Effective Tax Rate (%)	12.0	12.8	11.8	13.9	19.1

E = Morgan Stanley Research estimates; NA = Not Applicable; NM = Not Meaningful EPS includes extraordinary items and minority interest Source: Company data, Morgan Stanley Research

January 14, 2009 Infosys Technologies

### Risk-Reward Snapshot: Infosys Technologies (INFY.BO, Rs1,230, EW, PT Rs1,351)




### **Risk-Reward View: Macro Environment Remains the Key Risk**

Source: Company data, Morgan Stanley Research

Price Targ	et Rs1,351	Derived from the probability-weighted average of our bull-, base-, and bear case scenarios
Bull Case Rs2,000	19x Base Case Dec 09e EPS	<b>Better-than-expected growth:</b> Our bull case assumes pricing holds and the company continues to get business with better-than-expected volume growth. We forecast ~10% revenue and earnings growth with stable margins in US\$ terms in F2010e. [Probability = 0.05]
Base Case Rs1,560	15x Base Case Dec 09e EPS	<b>Steady growth:</b> Pricing pressure partly offset by rupee depreciation in F2010. Lower volume growth could lead to a single-digit revenue growth and flattish/marginally lower profits in F2010 in US\$ terms. [Probability = 0.6]
Bear Case Rs900	9x Base Case Dec 09e EPS	<b>Tougher macro environment:</b> Pricing pressure and lower volume of new businesses could lead to revenue decline of ~4-5% in USD terms in F2010. A ~150bp margin contraction could lead net profits to decline ~10-15% in US\$ terms in F2010. [Px = 0.35]

### Bear to Bull: Tech Spending Could Slow Down in US in C2009



Source: FactSet, Morgan Stanley Research

### **Investment Thesis**

- Overall market contraction, prospects of increasing pricing pressure and lack of certainty on budgets for 2009 could lead to challenging outlook for F2010 revenue growth in the near term.
- In a recession, clients of large offshore vendors could delay spending on moving work offshore.
- Infosys continues to see a tough environment and is likely to add 25,000 employees for F2009.

### **Key Value Drivers**

- Management execution and focus on maintaining profitability.
- Scale and scalability.
- Diversified client base.
- Strong operating cash flows.

### **Potential Catalyst**

- Higher-than-expected technology spending budgets for C2008-09.
- Any pricing improvement will drive margins positively.
- Rupee depreciation, if any, can be a positive catalyst.
- Any upward guidance revision over the coming quarters.

### **Key Risks**

- Significant rupee appreciation is a key risk.
- A sudden and significant slowdown in the US could hurt demand.
- Slowdown in the US with significant impact on spending budget of clients ]

### MORGAN STANLEY RESEARCH

January 14, 2009 Infosys Technologies

### Investment Case

### Summary & Conclusions

Infosys reported better-than-expected Dec08 results.

Revenue of Rs57.8bn (+6.8% QoQ, +35.5% YoY) was ahead of guidance and in line with our expectation. Strong EBIT margins at 31.9% (+203bps QoQ, +286bps YoY) driven by rupee depreciation against US\$. Net income of Rs16.4bn (+14.6% QoQ, +33.3% YoY) was also ahead of our expectations. Infosys met its US\$ revenue and net profit guidance in constant currency terms. FY09e US\$ revenue and EPS guidance at US\$4.67-4.71bn and US\$2.23 were revised down marginally to reflect cross currency movements and emerging pricing pressure.

Key Result Positives: 1) Infosys met its US\$ revenue and EPS guidance on constant currency basis. 2) Added 6k (gross) employees and hiring target increased to 27,000 (from 25,000 earlier) for FY09e. 3) Despite a challenging environment, BFSI and Retail verticals grew ahead of the company average at 4.1% and 2.9% QoQ, respectively (on constant currency basis). 4) Attrition rates improved to 11.8%, lowest in the last 10 quarters. 5) Management indicated no material cancellation of projects. 6) Top 10 clients grew faster than non top 10 at 3.2% QoQ on constant currency basis. 7) Secured 4 large deals (~US\$50-100m) during the quarter and has 10 more such deals in the pipeline.

Key Result Negatives: 1) Pricing declined by -1.8% QoQ on a constant currency basis and could fall further if the environment continues to worsen. 2) Subsidiaries continue to drag performance: Revenue of US\$116m (-10.3% QoQ) and net income of US\$7.4m (-20.4% QoQ). 3) New client additions (net) remained weak. 4) Weakness in Manufacturing (-3.7% QoQ), Telecom (-3.4% QoQ) and Europe (-1.2% QoQ) on constant currency basis. 5) Infosys consulting to break even next year as against in F2009 earlier.

Other Call Highlights: 1) Clients' budgets to be finalized by mid Feb-March. Budget may not be delayed this year but a likely to be lower YoY. 2) Multiple clients up for pricing renegotiation led to -1.8% QoQ price declines during the quarter. 3) Cash balance of US\$1.98bn and hedge position of US\$576m as on 31 December, 2008. Management does not expect any rupee appreciation in the near term. 4) Utilization improved from 74.1% to 74.8%.

Valuations: We maintain our Equal-weight rating on Infosys with a new price target of Rs1,351 (from Rs1,285) based on a probability-weighted average of our bull-, base-, and bear-case

scenarios. The stock has moved up 11% in the last month against the broad market (Sensex) correction of 6% over the same period. We do not see any near-term triggers for the stock. We are adjusting our FY10e/FY11e earnings estimates by ~1% (in rupee terms) post F3Q09 results. Given the worsening macro environment, we see limited upside for the stock in the near-medium term. We are raising our price target to factor in a higher probability for our base and a lower probability for our bear case for Infosys in the current environment, where vendors with good corporate governance, and credible track record (like Infosvs) could command premium valuations over peers, in our view. We now assume a probability of 60% for our base case, 35% for our bear-case scenario, and 5% for our bull-case scenario, or (Rs1,351 =0.05\*2,000 +0.6\*1,560+ 0.35\*900).

The stock currently trades at a ~12x F2009e EPS, which is near the lower end of its historical trading range. We believe that P/E comparisons remain the most appropriate valuation measure for Infosys, given the company's profitable track record and strong earnings visibility. Infosys has traded at an average one-year rolling P/E of 22x with a low of 11x. Another measure we use to support our price target is price/sales multiple comparison. Over the past two years, Infosys has traded at price/sales of ~3-7.5x, with an average of 5.5x. Our 12-month forward price target implies a price/sales multiple of ~3.5x.

Key risks include: 1) Infosys has high exposure to the banking, financial services, and insurance (BFSI) sectors (~34.9% of total), and any slowdown in this sector may adversely affect earnings. 2) Any significant rupee appreciation against the US dollar could impair operating margins and earnings. 3) If the US economy slows and corporates come under pressure to trim their technology spending on offshore activities, this could have an adverse impact on Infosys' revenue and earnings growth. 4) Any cut in the H1B visa quota would impair the onsite business.

Infosys: Income Statement (US\$ m, %)												
Year ending March 31st Dec-07 Sep-08 Dec-08 QoQ Yo												
Revenue	1,084	1,216	1,171	-3.7%	8.0%							
Operating Profit	312	359	371	3.3%	18.9%							
Operating Margins (%)	28.8%	29.5%	31.7%	215 bps	290 bps							
PAT	310	318	330	3.6%	6.5%							
EPADS	0.54	0.56	0.58	3.6%	7.4%							
Source: Company data, Morgan	Stanley Res	earch: As r	er US GAA	P								

ce: Company data, Morgan Stanley Research; As per US

Exhibit 1

### MORGAN STANLEY RESEARCH

January 14, 2009 Infosys Technologies

### Exhibit 2 Infosys: Trends in Quarterly Income Statement (Rs m,%)

Comment	YoY	QoQ	Dec-08	Sep-08	Dec-07	Year ending March 31st
Vol (+2%), Px(-6%), Re (+11%); Constant currency growth o						
1% qoq in US\$ terms	35.5%	6.8%	57,860	54,180	42,710	Revenue
	32.3%	6.4%	30,750	28,910	23,250	Cost of Goods
	39.3%	7.3%	27,110	25,270	19,460	Gross Profit
	129 bps	21 bps	46.9%	46.6%	45.6%	Gross Margins (%)
	22.7%	-7.2%	6,800	7,330	5,540	SG&A
	45.9%	13.2%	20,310	17,940	13,920	EBIDTA
	251 bps	199 bps	35.1%	33.1%	32.6%	EBIDTA Margins (%)
	22.2%	5.6%	1,870	1,770	1,530	Depreciation
	48.8%	14.0%	18,440	16,170	12,390	Operating Profit
Re dep (+4.7%), Cross currency (-1%),Utilizn(-1.3%)						
Others(-0.4%	286 bps	203 bps	31.9%	29.8%	29.01%	Operating Margins (%)
Include Fx loss of Rs2,180n	-75.9%	-42.4%	380	660	1,580	Other Income
	34.7%	11.8%	18,820	16,830	13,970	PBT
	45.2%	-4.0%	2,410	2,510	1,660	Тах
Include a tax reversal of Rs620m pertaining to earlier year	114 bps	-211 bps	12.8%	14.9%	11.7%	Tax rate (%)
	33.3%	14.6%	16,410	14,320	12,310	РАТ

Exhibit 3


### Infosys Guidance for 4Q09 and F2009

				Rs m		USD m				
	F1Q09	F2Q09	F3Q09	F4Q09e	F2009e	F1Q09	F2Q09	F3Q09	F4Q09e	F2009e
Revenue	48,540	54,180	57,860	54,940- 56,990	215,520-217,570	1,155	1,216	1,171	1,128-1,170	4,670-4,710
% qoq	6.9	11.6	6.8	-5 to -1.5	29.1-30.3	1.1	5.3	-3.7	-3.7 to -0.1	11.8-12.8
EPS/EPADS	22.8	25.0	28.7	26.5	102.9	0.54	0.56	0.58	0.55	2.23
% qoq	4.2	10.0	14.5	-7.6	26.2	-1.8	3.7	3.6	-5.2	9.9

Source: Company data, Morgan Stanley Research, \*EPS of Rs101.3 (+27.6%yoy) excld tax reversals at Rs930m in F2009. US\$ earnings of US\$2.20(+11.1%yoy) excld tax reversals of US\$19m in F2009; Assumed currency rates for AUD, GBP and EUR are 0.69/USD, 1.45/USD and 1.41/USD. If currencies (except INR) depreciate further against USD, it is negative for the guidance

Exhibit 4

# Q4 Revenue run rate back to FY08 levels with 2009 budgets likely to be lower than 2008



Source: Company data, Morgan Stanley Research

MORGAN STANLEY RESEARCH


January 14, 2009 Infosys Technologies

### Exhibit 5 Infosys: Subsidiaries continue to drag performance (US\$m, %)


Revenues US \$m	Mar-07	Jun-07	Sep-07	Dec-07	Mar-08	Jun-08	Sep-08	Dec-08	% qoq	% yoy
Infy BPO	44.7	49.2	52.7	64.0	69.4	72.6	72.6	67.1	-7.6%	4.8%
Infy Australia	32.0	35.4	34.4	32.6	36.6	34.1	30.8	26.0	-15.6%	-20.2%
Infy Consulting	13.5	12.8	16.3	16.6	15.9	17.7	17.7	13.5	-23.6%	-18.5%
Infy China	2.5	3.8	5.1	5.0	5.3	5.8	5.8	6.7	15.2%	32.7%
Infy Mexico			-	0.2	0.5	1.2	2.0	2.3	17.3%	1252.9%
Total	92.6	101.2	108.5	118.3	127.7	131.4	128.8	115.6	-10.3%	-2.4%
% of Consolidated Revenues	10.7	10.9	10.6	10.9	11.2	11.4	10.6	9.9		
Net profit/ (loss) US \$m										
Infy BPO	8.7	8.1	10.3	7.3	9.1	7.3	11.0	10.9	-1.1%	48.4%
Infy Australia	7.5	5.7	7.4	4.6	7.7	3.4	2.1	1.6	-22.1%	-64.5%
Infy Consulting	(11.0)	(0.8)	(12.0)	-	(0.1)	(1.5)	(1.1)	(2.7)	NM	NM
Infy China	(2.3)	(1.1)	(0.0)	(0.4)	(0.1)	(0.1)	(1.9)	(2.0)	NM	NM
Infy Mexico			(0.1)	(0.9)	(0.8)	(0.3)	(0.8)	(0.5)	NM	NM
Total	2.9	11.9	5.6	10.5	15.9	8.8	9.3	7.4	-20.7%	-30.1%
% of Consolidated Net Profit	1.1	4.5	2.1	3.4	5.1	2.9	2.9	2.2		

Source: Company data, Morgan Stanley Research


Exhibit 6



Source: Company data, Morgan Stanley Research




Source: Bloomberg, Company data, Morgan Stanley Research




Source: Bloomberg, Company data, Morgan Stanley Research Exhibit 9

### TCS PE relative discount to Infosys



Source: Bloomberg, Company data, Morgan Stanley Researce Exhibit 10

### Infosys PE relative to Sensex



Source: Bloomberg, Company data, Morgan Stanley Research

### MORGAN STANLEY RESEARCH

January 14, 2009 Infosys Technologies

### Exhibit 11 Infosys: Comparative Price Performance

Comp Peers/Index	1d	1w	1m	3m	6m	1yr	Ytd
INFOSYS	5.9	4.7	11.2	-6.9	-26.8	-21.5	10.1
HCL TECH	0.8	-13.7	1.5	-35.9	-54.4	-62.3	-5.6
SATYAM	-9.7	-81.4	-85.9	-88.5	-93.0	-92.4	-81.8
TCS	2.6	2.0	9.2	-8.2	-34.2	-46.9	10.0
WIPRO	5.7	-2.2	1.0	-15.4	-41.7	-50.8	3.0
I-FLEX	-1.5	-7.0	6.8	-15.1	-65.7	-69.2	-0.2
MPHASIS	0.2	-10.8	-2.3	-7.5	-26.2	-47.0	-3.6
POLARIS	-8.1	-26.6	-16.0	-30.1	-56.0	-72.4	-22.1
PATNI	-2.1	-14.9	-11.3	-22.8	-51.6	-61.6	-8.6
HEXAWARE	-1.3	-14.5	-3.7	-18.2	-62.3	-75.4	-6.4
TECH MAHINDRA	-5.1	-17.8	-10.6	-44.9	-66.5	-77.0	-5.7
MINDTREE	0.3	-6.8	-7.1	-8.2	-41.1	-52.1	-5.2
E-CLERX	-1.6	-5.8	-8.6	2.6	-54.1	-74.4	-2.7
EDUCOMP	-2.5	-26.7	-7.1	-11.1	-29.2	-57.2	-19.3
HCL INFO	-5.5	-15.0	1.5	-20.6	-40.7	-70.4	-17.8
INFOEDGE	-0.4	-0.8	2.2	-9.6	-54.4	-68.2	0.3
KPIT CUMMINS	-1.5	-16.1	-18.1	-14.3	-62.9	-81.0	-15.2
MASTEK	1.5	-6.3	-3.9	-33.3	-55.5	-53.2	-3.2
NIIT LTD	-1.7	-20.9	-6.8	-23.1	-77.1	-82.8	-12.6
NUCLEUS SOFT	5.8	-0.7	5.0	-41.6	-73.8	-85.2	10.6
SASKEN	-3.4	-21.9	-6.0	-44.0	-62.6	-82.4	-14.5
SUBEX	-4.7	-20.0	-16.8	-55.1	-69.4	-92.3	-16.6
TANLA	-16.8	-49.1	-44.0	-56.9	-79.8	-86.7	-34.9
BSE SENSEX	-0.4	-11.7	-6.4	-19.8	-32.7	-56.4	-6.0
MSCI INDIA IT IND	-3.5	-9.7	-7.7	-23.4	-43.5	-43.4	-5.3
NASDAQ COMP	0.5	-6.4	0.4	-16.1	-30.9	-36.6	-1.9
Source: Bloomberg, Compan	y data, Mor	gan Stanl	ey Resea	arch; Bas	ed on clo	se price as	at 13 <sup>m</sup>

January2009

### MORGAN STANLEY RESEARCH

January 14, 2009 Infosys Technologies

### Exhibit 12 Infosys: Quarterly Metrics for Dec08

	Mar-07	Jun-07	Sep-07	Dec-07	Mar-08	Jun-08	Sep-08	Dec-08	Comments
Geographical (% of Revenues)									
North America	62.6	62.6	62.6	62.3	60.7	62.6	61.5	64.5	
Europe	26.6	26.8	27.4	28.6	29.3	27.3	28.1	25.5	
India	1.5	1.8	1.0	1.2	1.3	1.3	1.3	1.2	
Others	9.3	8.8	9.0	7.9	8.7	8.8	9.1	8.8	
Onsite Offshore (% of revenues)									
Offshore	50.2	50.3	51.2	52.2	52.5	52.5	52.7	54.2	
Onsite	49.8	49.7	48.8	47.8	47.5	47.5	47.3	45.8	
Industry Verticals (% of Revenues):									
BFSI	37.0	36.1	36.5	36.8	33.9	34.5	33.4	34.9	
Manufacturing	12.9	13.6	13.9	14.8	16.4	18.4	20.1	19.6	
Telecom	21.9	22.0	20.6	21.1	22.5	19.7	19.0	16.7	
Retailing	10.8	10.8	12.5	12.0	11.9	12.2	12.1	12.6	
Others	17.4	17.5	16.5	15.5	15.3	15.2	15.4	16.2	
Client Concentration:									
									9 in BFSI, 6 in
Gross Clients Added	34	35	48	47	40	49	40	30	Manufacturing, 4 in Retail
Total Clients	500	509	520	530	538	567	586	583	Declined for the first time
Net Clients Added	12	9	11	10	8	29	19	(3)	since F2002
Top client's (%)	8.5	8.6	7.9	9.5	10.3	7.9	7.6	6.2	
Top 5 clients' (%)	21.3	21.4	19.5	21.6	22.0	19.9	18.6	17.3	
Top 10 clients' (%)	33.4	32.3	29.9	32.5	32.0	30.1	28.0	27.2	
Repeat Business (%)	93.3	99.5	97.7	96.3	95.0	99.6	99.8	97.1	
Client Size:									
\$1 Mn clients	275	285	295	305	310	325	325	323	
\$5 Mn clients	107	113	122	128	141	146	151	150	
\$10 Mn clients	71	75	77	81	89	91	94	102	
\$20 Mn clients	36	40	44	45	47	53	56	58	
\$30 Mn clients	25	26	30	30	32	33	34	37	
\$40 Mn clients	16	18	22	22	22	25	26	26	
\$50 Mn clients	12	13	16	17	18	18	20	20	
\$100 Mn clients	3	3	3	4	6	6	5	4	
Billing Rates (US\$/Person-Month):									
Onsite Billing Rate	11,652	11,817	12,165	12,295	12,289	12,291	12,370	11,649	
Offshore Billing Rate	4,792	4,842	4,969	5,036	5,063	5,060	5,064	4,830	
Blended Billing Rate	7,041	7,115	7,251	7,306	7,321	7,334	7,331	6,864	
Utilization Rates (%)									
Including Trainees	66.9	70.5	70.3	70.1	70.2	69.8	69.4	68.5	Lower utilization impacted
Excluding Trainees	72.5	73.9	77.8	77.4	75.7	72.3	73.7	74.5	margins
Contract Type (% of Revenues)									
Fixed Price	25.9	27.5	29.8	32.8	33.2	32.8	34.1	36.3	
Time & Materials	74.1	72.5	70.2	67.2	64.6	64.8	63.8	63.7	
DSO (US GAAP)	67	67	65	62	72	64	60	56	Lowest in last 12 quarters
Employees:	0.	0.				01			FY09 Hiring target raised
IT and Consulting employees	61,015	63,649	67,528	73,206	74,892	77,095	82,979	86,137	to 27,000 from 25,000
Infosys BPO	11,226	12,322	12,973	15,395	16,295	17,284	17,327	16,941	Declined for the first time
No of Employees	72,241	75,971	80,501	88,601	91,187	94,379	100,306	103,078	
Attrition Rates (%)	13.7	13.7	14.2	13.7	13.4	13.6	12.8	11.8	Lowest in last 10 quarters
	2,809	3,730	4,530	8,100	2,586	3,192	5,927	11.0	Lowest in last to qualters

8

### MORGAN STANLEY RESEARCH

January 14, 2009 Infosys Technologies

### Exhibit 13 Infosys: Trends in Revenue Distribution (USD m, %)

	Mar-07	Jun-07	Sep-07	Dec-07	Mar-08	Jun-08	Sep-08	Dec-08	Comments
Geographical (USDm)									
North America	540	581	640	675	693	723	748	756	
Europe	229	249	280	310	335	315	342	299	
Total	863	928	1,022	1,084	1,142	1,155	1,216	1,171	
QoQ growth (%)									
North America	4.1	7.6	10.1	5.6	2.6	4.3	3.4	1.0	+1.5% in Constant currency
Europe	4.3	8.4	12.6	10.7	7.9	-5.8	8.4	-12.6	-1.2% in Constant currency
Total	5.1	7.6	10.1	6.1	5.4	1.1	5.3	-3.7	+5.8% in Constant currency
YoY growth (%)									
North America	40.0	37.5	34.7	30.2	28.4	24.4	16.9	11.9	
Europe	51.7	43.8	45.6	40.9	45.8	26.8	22.0	-3.7	
Total	45.4	40.6	37.1	32.1	32.4	24.4	19.0	8.1	
Key Verticals (USDm)									
BFSI	319	335	373	399	387	398	406	409	
Manufacturing	111	126	142	160	187	213	244	230	
Telecom	189	204	211	229	257	228	231	196	
Retailing	93	100	128	130	136	141	147	148	
QoQ growth (%)									
BFSI	14.5	5.0	11.3	6.9	-3.0	2.9	1.9	0.7	+4.1% in Constant currency
Manufacturing	6.6	13.4	12.5	12.9	16.7	13.5	15.0	-6.1	-3.7% in Constant currency
Telecom	34.1	8.1	3.1	8.6	12.3	-11.4	1.5	-15.3	-3.4% in Constant currency
Retailing	38.9	7.6	27.5	1.8	4.5	3.7	4.4	0.3	+2.9% in Constant currency
YoY growth (%)									
BFSI	49.4	39.4	33.8	25.9	21.3	18.9	8.9	2.5	
Manufacturing	29.4	31.9	36.1	52.7	68.3	68.4	72.0	43.1	
Telecom	95.4	74.7	49.4	52.3	36.0	11.4	9.7	-14.5	
Retailing	54.0	56.5	90.4	50.9	45.9	40.6	15.2	13.5	
Growth in Billing Rates									
QoQ growth (%)									
Onshore	1.7	1.4	2.9	1.1	0.0	0.0	0.6	-5.8	
Offsite	1.4	1.0	2.6	1.3	0.5	0.0	0.1	-4.6	
Blended Rate	1.7	1.0	1.9	0.8	0.2	0.2	0.0	-6.4	-1.8% in Constant currency
YoY growth (%)									
Onshore	6.3	6.7	8.3	7.4	5.5	4.0	1.7	-5.3	
Offsite	4.4	5.3	6.9	6.5	5.6	4.5	1.9	-4.1	
Blended Rate	6.3	5.5	6.2	5.5	4.0	3.1	1.1	-6.0	

Source: Company data, Morgan Stanley Research

Exhibit 14

### MORGAN STANLEY RESEARCH

January 14, 2009 Infosys Technologies

### Infosys: Top Clients Metrics (USDm, %)

Top Clients (% of revenue)	Mar-07	Jun-07	Sep-07	Dec-07	Mar-08	Jun-08	Sep-08	Sep-08	Comments
Тор 1	8.5	8.6	7.9	9.5	10.3	7.9	7.6	6.2	
Top 2-5	12.8	12.8	11.6	12.1	11.7	12.0	11.0	11.1	
Тор 5	21.3	21.4	19.5	21.6	22.0	19.9	18.6	17.3	
Top 6-10	12.1	10.9	10.4	10.9	10.0	10.2	9.4	9.9	
Тор 10	33.4	32.3	29.9	32.5	32.0	30.1	28.0	27.2	
Non Top 10	66.6	67.7	70.1	67.5	68.0	69.9	72.0	72.8	
Revenue (USDm)									
Ter 4	70	00	04	100	440	04	00	70	Largely due to appreciation of USD vs
Top 1	73	80	81	103	118	91	92	73	UKP
Top 2-5	110	119	119	131	134	139	134	130	
Top 5	184	199	199	234	251	230	226	203	
Top 6-10	104	101	106	118	114	118	114	116	
Top 10	288	300	306	352	365	348	340	319	
Non Top 10	575	628	716	732	777	807	875	853	
QoQ Growth %									
Top 1	29.5	8.8	1.2	27.5	14.2	-22.4	1.3	-21.4	
Тор 2-5	12.1	7.6	-0.2	10.6	1.9	3.7	-3.5	-2.8	
Тор 5	18.5	8.1	0.3	17.5	7.3	-8.5	-1.6	-10.4	
Top 6-10	5.1	-3.1	5.1	11.2	-3.3	3.2	-3.0	1.5	
Top 10	13.2	4.0	1.9	15.3	3.7	-4.9	-2.1	-6.4	
Non Top 10	1.4	9.4	14.0	2.1	6.1	4.0	8.4	-2.6	
YoY Growth %									
Top 1	163.0	108.4	64.1	81.8	60.4	14.3	14.5	-29.5	
Top 2-5	33.9	31.3	10.4	33.2	21.0	16.7	12.8	-0.9	
Тор 5	66.5	54.3	27.3	50.9	36.7	15.7	13.5	-13.4	
Top 6-10	41.9	25.6	19.8	19.0	9.4	16.5	7.5	-1.9	
Top 10	56.7	43.2	24.6	38.5	26.8	16.0	11.4	-9.6	
Non Top 10	40.3	39.3	43.2	29.2	35.2	28.5	22.2	16.5	

Source: Company data, Morgan Stanley Research

Exhibit 15

### MORGAN STANLEY RESEARCH

January 14, 2009 Infosys Technologies

### Global Software Valuations: P/E and PEG Ratio

Company	Ticker	Curr	Price (Local)	M Cap (\$mil)		6 (Respect Currency)	ive		P/E (x)		E	PS Growt	h	EPS CAGR	
			. ,	. ,	FY08	FY09e	FY10e	FY08	FY09e	FY10e	FY08	FY09e	FY10e	08-10	PEG
US Listed															
Accenture	ACN	USD	33	20,061	2.7	2.9	3.1	12.5	11.5	10.7	34.5%	8.7%	6.9%	7.8%	1.5
Amdocs*	DOX	USD	20	3,993	2.1	2.2	2.4	9.4	9.1	8.2	25.1%	3.1%	10.6%	6.8%	1.3
BearingPoint *	BE	USD	2	7	-84.0	-13.6	-1.0	NM	NM	NM	66.3%	NM	NM	NM	NM
Cognizant Solutions	CTSH	USD	20	5,739	1.2	1.4	1.5	17.1	13.6	12.9	49.2%	25.2%	6.0%	15.2%	0.9
Computer Sciences *	CSC	USD	36	5,462	3.8	4.2	4.3	9.4	8.5	8.4	11.6%	10.1%	1.0%	5.5%	1.6
Infosys - ADR	INFY	USD	26	14,820	2.0	2.1	2.2	12.7	12.2	11.6	32.7%	4.2%	5.9%	5.0%	2.4
Patni - ADR	PTI	USD	5	325	1.7	1.3	1.2	3.0	4.0	4.2	15.0%	NM	NM	NM	NM
Satyam - ADR	SAY	USD	1	492	1.2	1.4	1.3	1.2	1.1	1.1	32.4%	11.3%	NM	3.5%	0.3
Wipro - ADR	WIT	USD	7	10,758	0.6	0.5	0.6	13.1	13.9	12.7	25.1%	NM	9.6%	1.5%	9.4
European Listed															
Cap Gemini	CAP	EUR	27	5,253	2.4	2.9	2.9	11.4	9.3	9.4	54.2%	22.6%	NM	10.1%	0.9
Logica PLC	LOG	GBp	72	1,677	10.4	9.7	8.8	6.8	7.3	8.2	24.4%	NM	NM	NM	NM
India Listed															
HCL Tech	HCLT	INR	109	1,525	19.9	21.2	21.0	5.5	5.1	5.2	25.5%	6.7%	NM	2.9%	1.8
Hexaware	HEXW	INR	20	58	7.7	5.2	6.2	2.6	3.8	3.2	NM	NM	19.3%	NM	NM
Infosys - Local	INFO	INR	1,230	14,471	81.3	102.9	107.0	15.1	12.0	11.5	23.8%	26.6%	4.0%	14.8%	0.8
MphasiS @	MPHL	INR	150	644	14.1	14.1	23.3	10.6	10.6	6.4	15.7%	NM	65.3%	28.6%	0.4
Patni - Local	PATNI	INR	119	340	33.3	25.5	30.0	3.6	4.6	4.0	29.5%	NM	17.5%	NM	NM
Satyam - Local	SCS	INR	31	439	24.7	34.0	34.5	1.3	0.9	0.9	17.8%	37.4%	1.5%	18.1%	0.1
TCS	TCS	INR	523	10,525	51.3	52.9	56.9	10.2	9.9	9.2	21.5%	3.2%	7.6%	5.4%	1.8
Tech Mahindra	TECHM	INR	233	626	58.9	75.0	72.3	3.9	3.1	3.2	18.9%	27.4%	NM	10.8%	0.3
Wipro - Local	WPRO	INR	241	7,233	22.5	26.8	28.3	10.7	9.0	8.5	10.3%	19.0%	5.7%	12.2%	0.7
BPO															
Genpact	G	USD	9	1,851	0.46	0.72	0.73	18.7	12.0	11.8	6.4%	55.9%	1.8%	26.0%	0.5
WNS	WNS	USD	7	309	0.87	1.11	1.13	8.3	6.6	6.4	11.4%	27.2%	2.0%	13.9%	0.5
Convergys	CVG	USD	7	891	1.23	1.05	0.83	5.9	7.0	8.8	4.9%	NM	NM	NM	NM
Teletech	TTEC	USD	8	537	1.05	1.21	0.96	7.9	6.8	8.6	40.9%	16.1%	NM	NM	NM
EXL*	EXLS	USD	9	246	0.93	0.38	0.42	9.2	22.5	20.3	132.5%	NM	10.9%	NM	4.2
ADP*	ADP	USD	39	19,584	2.18	2.38	2.58	17.7	16.2	15.0	8.5%	9.2%	8.3%	8.7%	1.9
ACS*	ACS	USD	45	4,136	3.53	3.67	4.25	12.9	12.4	10.7	33.2%	4.0%	15.8%	9.7%	1.6

Prices as on January13, 2009 for India listed stocks and 12th January2009 for others

E = Morgan Stanley Research estimates, except for those marked with an asterisk (\*), which are consensus estimates as provided by FactSet

M = Not Meaningful @ MphasiS EPS include EDS India from F2007; Mphasis FY09e represent actual EPS for the period of 7 months from April08-October08; FY10e represent our estimates for the period of Nov08-Oct09 #,Amdocs, ACS, ADP, Teletech, Convergys F2008 EPS numbers represent estimates.

WNS EPS represent company-adjusted numbers; Genpact EPS represent MS adjusted numbers (GAAP EPS adjusted for formation-related expense and FBT costs). Estimates for Indian ADRs are taken from FactSet.

Morgan Stanley does not provide research coverage of the listed ADRs associated with the underlying ordinary shares listed above. As a courtesy, Morgan Stanley may include an ADR price target or an ADR share price in US dollars in its research reports. Unless otherwise stated, any ADR price target is only a conversion calculation using the appropriate currency exchange rate and ordinary shares versus ADR ratio. Investors should be aware that such calculations do not take into account any issues or risks associated with investing in an ADR, including but not limited to liquidity, voting rights, dividends, volatility, and currency or exchange rate fluctuations.

Bearing Point, Cognizant, EDS, Cap Gemini, Logica, Hexaware and Patni have a December-ending fiscal year, Accenture has an August-ending FY, Amdocs has a September-ending FY, HCL Tech has a June-ending FY, and the rest have a March-ending FY. For companies with a December-ending fiscal year, F2008 represents their actual CY07 numbers.

Sources: Company data, FactSet, Morgan Stanley Research

### MORGAN STANLEY RESEARCH

January 14, 2009 Infosys Technologies

### **Company Description**

Infosys Technologies provides IT consulting and software services to global organizations. It offers offshore-based software services such as application development, software maintenance, consulting, and BPO, and establishes software centers for its customers. Infosys's solutions cover a wide range of business areas.

India Software

**Industry View: Cautious** 

### **MSCI Country: India**

Asia Strategist's Recommended Weight: 2.9% MSCI Asia/Pac All Country Ex Jp Weight: 6.7%

#### MORGAN STANLEY RESEARCH

January 14, 2009 Infosys Technologies

### MORGAN STANLEY

**ModelWare** 

Morgan Stanley ModelWare is a proprietary analytic framework that helps clients uncover value, adjusting for distortions and ambiguities created by local accounting regulations. For example, ModelWare EPS adjusts for one-time events, capitalizes operating leases (where their use is significant), and converts inventory from LIFO costing to a FIFO basis. ModelWare also emphasizes the separation of operating performance of a company from its financing for a more complete view of how a company generates earnings.

Disclosure Section The information and opinions in Morgan Stanley Research were prepared or are disseminated by Morgan Stanley Asia Limited (which accepts the responsibility for its contents) and/or Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z, regulated by the Monetary Authority of Singapore, which accepts the responsibility for its contents), and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 20008434H, regulated by the Monetary Authority of Singapore, which accepts the responsibility for its contents), and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 20008434H, regulated by the Monetary Authority of Singapore, which accepts the responsibility for its contents), and/or Morgan Stanley Taiwan Limited and/or Morgan Stanley & Co International plc, Seoul Branch, and/or Morgan Stanley Australia Limited (A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents), and/or Morgan Stanley India Company Private Limited and their affiliates (collectively, "Morgan Stanley"). For important disclosures, stock price charts and rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley

Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Equity Research Management), New York, NY, 10036 USA.

### Analvst Certification

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Vipin Khare.

Unless otherwise stated, the individuals listed on the cover page of this report are research analysts.

### **Global Research Conflict Management Policy**

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflictpolicies.

Important US Regulatory Disclosures on Subject Companies As of December 31, 2008, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: Infosys Technologies, Tata Consultancy Services. Within the last 12 months, Morgan Stanley has received compensation for investment banking services from Mindtree Ltd.

Within the last 12 months, Morgan Stanley has received compensation for investment banking services from Mindtree Ltd.. In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Genpact Limited, HCL Technologies, Hexaware Technologies Limited, Infosys Technologies, Mindtree Ltd., Patni Computer Systems, Satyam Computer Services, Tata Consultancy Services, Wipro Ltd., WNS Global Services. Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following company: Genpact Limited, HCL Technologies, Hexaware Technologies Limited, Infosys Technologies, Mindtree Ltd., Patni Computer Systems, Satyam Computer Services, Tata Consultancy Services, Wipro Ltd., WNS Global Services. Within the last 12 months, Morgan Stanley has either provided or is providing non-investment banking, securities-related services to and/or in the past the patient relationship with the following company: Genpact Limited, and the provided or is providing non-investment banking, securities-related services to and/or in the past within the last 12 months, Morgan Stanley has either provided or is providing non-investment banking, securities-related services to and/or in the past

has entered into an agreement to provide services or has a client relationship with the following company: Mindtree Ltd.. The research analysts, strategists, or research associates principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues.

Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

### STOCK RATINGS

Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should carefully read Morgan Stanley investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations

### **Global Stock Ratings Distribution**

(as of December 31, 2008)

For disclosure purposes only (in accordance with NASD and NYSE requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively.

	Coverage Universe		Investment Banking Clients (IBC				
-		% of		% of %	% of % of Rating		
Stock Rating Category	Count	Total	Count	Total IBC	Category		
Overweight/Buy	811	34%	240	40%	30%		
Equal-weight/Hold	1060	45%	271	45%	26%		
Not-Rated/Hold	33	1.4%	8	1.3%	24.2%		
Underweight/Sell	463	20%	87	14%	19%		
Total	2,367		606				

#### MORGAN STANLEY RESEARCH

January 14, 2009 Infosys Technologies

Data include common stock and ADRs currently assigned ratings. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations. Investment Banking Clients are companies from whom Morgan Stanley or an affiliate received investment banking compensation in the last 12 months.

### Analyst Stock Ratings

Overweight (O or Over) - The stock's total return is expected to exceed the total return of the relevant country MSCI Index, on a risk-adjusted basis over the next 12-18 months. Equal-weight (E or Equal) - The stock's total return is expected to be in line with the total return of the relevant country MSCI Index, on a risk-adjusted basis over the next 12-18 months. Not-Rated/Hold (NA or NAV) - Currently the analyst does not have adequate conviction about the stock's total return relative to the relevant country

MSCI Index, on a risk-adjusted basis, over the next 12-18 months. Please note that NA or NAV may also be used to designate stocks where a rating is not currently available for policy reasons. For the current list of Not-Rated/Hold stocks as counted above in the Global Stock Ratings Distribution

Table, please email morganistanley.research@morganistanley.com. Underweight (U or Under) - The stock's total return is expected to be below the total return of the relevant country MSCI Index, on a risk-adjusted basis, over the next 12-18 months.

Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.

#### Analyst Industry Views

Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below. In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below. Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below.

broad market benchmark, as indicated below. Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index.

### Other Important Disclosures

Morgan Stanley produces a research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in this or other research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Client Link at www.morganstanley.com.

For a discussion, if applicable, of the valuation methods used to determine the price targets included in this summary and the risks related to achieving these targets, please refer to the latest relevant published research on these stocks.

Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the individual financial circumstances and objectives of persons who receive it. The securities/instruments discussed in Morgan Stanley Research may not be suitable for all investors. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them.

Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The "Important US Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities or derivatives of securities of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities or derivatives of securities of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons

Morgan Stanley and its affiliate companies do business that relates to companies/instruments covered in Morgan Stanley Research, including market making and specialized trading, risk arbitrage and other proprietary trading, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis.

With the exception of information regarding Morgan Stanley, research prepared by Morgan Stanley Research personnel are based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley Research personnel conduct site visits from time to time but are prohibited from accepting payment or reimbursement by the company of travel expenses for such visits

The value of and income from your investments may vary because of changes in interest rates or foreign exchange rates, securities prices or market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in your securities transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. Unless otherwise stated, the cover page provides the closing price on the primary exchange for the subject company's securities/instruments.

To our readers in Taiwan: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your To our readers in Talwan: Information on securities/instruments that trade in Talwan is distributed by Morgan Stanley Talwan Limited ("MSTL"). Such information is for your reference only. Information on any securities/instruments issued by a company owned by the government of or incorporated in the PRC and listed in on the Stock Exchange of Hong Kong ("SEHK"), namely the H-shares, including the component company stocks of the Stock Exchange of Hong Kong ("SEHK")'s Hang Seng China Enterprise Index; or any securities/instruments issued by a company that is 30% or more directly- or indirectly-owned by the government of or a company incorporated in the PRC and traded on an exchange in Hong Kong or Macau, namely SEHK's Red Chip shares, including the component company of the SEHK's China-affiliated Corp Index is distributed only to Talwan Securities Investment Trust Enterprises ("SITE"). The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley Interprise ("SITE"). of Morgan Stanley. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.

To our readers in Hong Kong: Information is distributed in Hong Kong by and on behalf of, and is attributable to, Morgan Stanley Asia Limited as part of its regulated activities in Hong Kong. If you have any queries concerning Morgan Stanley Research, please contact our Hong Kong sales representatives.

Certain information in Morgan Stanley Research was sourced by employees of the Shanghai Representative Office of Morgan Stanley Asia Limited for the use of Morgan Stanley Asia Limited.

Morgan Stanley Research is disseminated in Japan by Morgan Stanley Japan Securities Co., Ltd.; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents); in Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore, which accepts responsibility for its contents; in Australia by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services licence No. 233742, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley India Company Private Limited; in Canada by Morgan Stanley Canada Limited, which has approved of, and has agreed to take responsibility for, the contents of Morgan Stanley Research in Canada; in Germany by Morgan Stanley Bank AG, Frankfurt am Main, regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin); in Spain by Morgan Stanley, S.V., S.A., a Morgan Stanley group company, which is supervised by the Spanish Securities Markets Commission (CNMV) and states that Morgan Stanley Research has been written and distributed in accordance with the rules of conduct applicable to financial research as established under Spanish regulations; in the United States by Morgan Stanley & Co. Incorporated, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized and regulated by Financial Services Authority, disseminates in the UK research that it has prepared, and approves solely for the purposes of section 21 of the Financial Services and Markets Act 2000, research which has been prepared by any of its affiliates. Private U.K. investors should obtain the advice of their Morgan Stanley & Co. International plc representative about the investments concerned. In Australia, Morgan Stanley & Co.

#### MORGAN STANLEY RESEARCH

January 14, 2009 Infosys Technologies

Research, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. RMB Morgan Stanley (Proprietary) Limited is a member of the JSE Limited and regulated by the Financial Services Board in South Africa. RMB Morgan Stanley (Proprietary) Limited is a joint venture owned equally by Morgan Stanley International Holdings Inc. and RMB Investment Advisory (Proprietary) Limited, which is wholly owned by FirstRand Limited.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA), and is directed at wholesale customers only, as defined by the DFSA. This research will only be made available to a wholesale customer who we are satisfied meets the regulatory criteria to be a client.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided in accordance with a contract of engagement on investment advisory concluded between brokerage houses, portfolio management companies, non-deposit banks and clients. Comments and recommendations stated here rely on the individual opinions of the ones providing these commendations and recommendations and recommendations. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.

The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data. The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property of MSCI and S&P.

Morgan Stanley has based its projections, opinions, forecasts and trading strategies regarding the MSCI Country Index Series solely on publicly available information. MSCI has not reviewed, approved or endorsed the projections, opinions, forecasts and trading strategies contained herein. Morgan Stanley has no influence on or control over MSCI's index compilation decisions.

Morgan Stanley Research, or any portion hereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Morgan Stanley Research is disseminated and available primarily electronically, and, in some cases, in printed form.

Additional information on recommended securities/instruments is available on request.

**The Americas** 1585 Broadway New York, NY 10036-8293 **United States** Tel: +1 (1) 212 761 4000

### Europe 20 Bank Street, Canary Wharf London E14 4AD United Kingdom Tel: +44 (0) 20 7 425 8000

### Japan 4-20-3 Ebisu, Shibuya-ku Tokyo 150-6008 Japan Tel: +81 (0) 3 5424 5000

### Asia/Pacific 1 Austin Road West Kowloon Hong Kong Tel: +852 2848 5200

### Industry Coverage:India Software

Company (Ticker)	Rating (as of) Price	ce (01/12/2009)
Vipin Khare		
Genpact Limited (G.N)	E (08/26/2008)	US\$8.63
HCL Technologies (HCLT.BO)	U (09/29/2008)	Rs108.6
Hexaware Technologies Limited (HEXT.BO)	E (02/22/2008)	Rs19.8
Infosys Technologies (INFY.BO)	E (07/14/2008)	Rs1,230.2
Mindtree Ltd. (MINT.BO)	NA (06/29/2008)	Rs224.05
MphasiS Limited (MBFL.BO)	E (11/09/2007)	Rs149.75
Patni Computer Systems (PTNI.BO)	E (05/01/2008)	Rs118.5
Satyam Computer Services (SATY.BO)	U (12/17/2008)	Rs31.25
Tata Consultancy Services (TCS.BO)	E (04/22/2008)	Rs522.8
Tech Mahindra Limited (TEML.BO)	E (01/29/2008)	Rs232.6
WNS Global Services (WNS.N)	U (08/05/2008)	US\$7.26
Wipro Ltd. (WIPR.BO)	E (01/29/2008)	Rs241.1

Stock Ratings are subject to change. Please see latest research for each company.

© 2009 Morgan Stanley